Overview

Dose-escalation Study of Combination BMS-936558 (MDX-1106) and Ipilimumab in Subjects With Unresectable Stage III or Stage IV Malignant Melanoma

Status:
Completed

Trial end date:
2019-04-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to determine the safety and tolerability of treatment with BMS-936558 (MDX-1106) in combination with Ipilimumab (BMS-734016) when given at the same time or as a sequenced regimen in subjects with unresectable Stage III or Stage IV malignant melanoma (MEL)

Phase:

Phase 1

Details

Lead Sponsor:

Bristol-Myers Squibb

Collaborators:

Medarex
Ono Pharma USA Inc

Treatments:

Antibodies, Monoclonal
Ipilimumab
Nivolumab